Inferior vena cava

FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

Retrieved on: 
Wednesday, February 28, 2024

Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Key Points: 
  • Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.
  • The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.
  • FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care.
  • “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley.

Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement of $700MM with 40 States Nationwide

Retrieved on: 
Monday, January 22, 2024

TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.  J&J has agreed to over $300MM above the $400MM that the company had reserved for this particular case. This first major settlement comes in conjunction with a dispute with its own shareholders, including a large fund in San Diego that determined J&J's concealment is tantamount to securities fraud – an opinion which a New Jersey Judge recently certified.

Key Points: 
  • TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.
  • J&J attempted a bankruptcy filing and a $9 billion offering to resolve that litigation, but the amount was rejected as unlawful.
  • The proposal by J&J would essentially provide the average settlement amount of each talc case to be approximately $150K per—a figure woefully short considering the severity of the victims' injuries.
  • Their loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

Inteleos Unveils Two New Point-of-Care Ultrasound Certifications

Retrieved on: 
Tuesday, September 26, 2023

ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, through its Point-of-Care Ultrasound (POCUS) Certification Academy (PCA), today announced the launch of an Inferior Vena Cava (IVC) certification and a Critical Care Specialty certification.

Key Points: 
  • ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, through its Point-of-Care Ultrasound (POCUS) Certification Academy (PCA), today announced the launch of an Inferior Vena Cava (IVC) certification and a Critical Care Specialty certification.
  • The PCA provides certification and educational resources for clinicians and is dedicated to ensuring quality patient care globally by upholding ultrasound standards with independently validated certifications.
  • The IVC Clinical Certificate and the Critical Care Specialty Certification include case-based assessments that simulate real-life clinical encounters and peer evaluations that determine practical skills and the user’s ability to interpret and diagnose findings.
  • “POCUS is not just an imaging tool, it's a compassionate touchpoint in patient care and a revolution in healthcare.

Teleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange

Retrieved on: 
Friday, September 15, 2023

WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange.

Key Points: 
  • WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange.
  • Vizient, Inc ., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.
  • The VPS Rhythm™ DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.
  • This device works in concert with the Arrow™ PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.

$3.3M Verdict Will Stand In Case Citing Bard's Defective IVC Blood Clot Filter

Retrieved on: 
Thursday, August 17, 2023

MADISON, Wis., Aug. 17, 2023 /PRNewswire/ -- A three-judge panel of the U.S. Court of Appeals for the Seventh Circuit has ruled that a $3.3 million jury verdict against medical device company Bard will stand, denying the company's bid for a new trial in an IVC filter product defect case.

Key Points: 
  • Bard's appellate briefing requesting a new trial stemmed from an alleged discrepancy between an expert witness's pretrial testimony and later trial testimony.
  • We're pleased that this panel of judges affirmed both the jury's verdict in Ms. Johnson's case and the federal district court's final judgment on that verdict."
  • The plaintiff in this case received the IVC filter implant ahead of a surgical procedure on her legs.
  • Mr. Martin told jurors in various IVC filter defect cases that Bard's failure to warn about the products' design flaws made the company's IVC filters a "ticking time bomb."

Legal-Bay Pre-Settlement Funding to Add Mesothelioma Cases for Funding Along with Talc After Large $18MM Verdict

Retrieved on: 
Monday, July 31, 2023

TRENTON, N.J., July 31, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they are now adding mesothelioma victims to their list of Johnson & Johnson talc plaintiffs. The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict. Both J&J and plaintiffs/lawyers await the next steps in what has been a painfully slow process.

Key Points: 
  • The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict.
  • While J&J has offered to settle the cases, the amount seems to be a fraction of what juries are awarding in both talc and mesothelioma verdicts of late."
  • Legal-Bay is also funding loans for lawsuits on Round Up cases, Essure, Juul e-Cigarettes, Hernia Mesh, IVC Filters, and Exactech hip and knee recall cases.
  • Their lawsuit loans funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

Pre-Settlement Funding Firm Expects Johnson & Johnson Talcum Based Baby Powder Cases to Settle By Year's End

Retrieved on: 
Friday, May 5, 2023

NEW BRUNSWICK, N.J., May 5, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they expect a global settlement to be reached in the landmark Johnson & Johnson Baby Powder Talc cases. It will be one of the largest mass tort settlements in U.S. history, costing J&J over $10 billion to resolve over 100,000 claims. 

Key Points: 
  • NEW BRUNSWICK, N.J., May 5, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they expect a global settlement to be reached in the landmark Johnson & Johnson Baby Powder Talc cases.
  • It will be one of the largest mass tort settlements in U.S. history, costing J&J over $10 billion to resolve over 100,000 claims.
  • Legal-Bay is also funding Round Up cases, Essure, Juul e-Cigarettes, Hernia Mesh, IVC Filters, and Exactech hip and knee recall cases.
  • To apply, please visit the company's website HERE or call toll-free at: 877.571.0405 where agents are available to answer your questions.

Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States

Retrieved on: 
Tuesday, May 2, 2023

The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.

Key Points: 
  • The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.
  • The next-generation VPS Rhythm® DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity.
  • The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement.
  • This device works in concert with the Arrow® PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.

Legal-Bay Pre-Settlement Funding Announces Johnson & Johnson to Pay Out $8.9 BILLION in Damages to Plaintiffs in Talcum Powder Lawsuit

Retrieved on: 
Thursday, April 6, 2023

NEW BRUNSWICK, N.J., April 6, 2023 /PRNewswire/ -- Legal-Bay LLC, the premier Pre Settlement Funding Company, reports that Johnson & Johnson will pay out a whopping $8.9BB in damages to settle the 60,000+ lawsuits brought against them by plaintiffs who claim the baby powder is directly to blame for their ovarian cancer. The pharma giant previously proposed a $2BB settlement, but with this latest 8.9BB offering hopes to close out their legal troubles once and for all.

Key Points: 
  • The pharma giant previously proposed a $2BB settlement, but with this latest 8.9BB offering hopes to close out their legal troubles once and for all.
  • The company has long been aware of the health risks associated with their talcum-based baby powder.
  • However, our sources representing plaintiffs do not believe the $150K average talc settlement amount is sufficient based on the damages.
  • Legal-Bay's lawsuit funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE)

Retrieved on: 
Thursday, February 23, 2023

CHICAGO and FAIRFAX, Va., Feb. 23, 2023 /PRNewswire/ -- Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).

Key Points: 
  • PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers.
  • The study was conducted at 54 sites in the United States between Oct. 10, 2015, and March 31, 2019.
  • During that time, filters were implanted in 1,421 patients, of which 1,019 patients had an existing deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • Approximately half of the patients in the study had their filters removed within 3 months of placement without complication or recurrence of DVT or PE, according to study authors.